LGALS9 and neoplasm: A targeted delivery system composed of a cationic liposome-encapsulated TGF-β siRNA combined with galectin-9 inhibitors disrupted adenosine-dependent inhibition by tumour-associated macrophages (TAMs), significantly increasing the tumour infiltration density of CAR-NK cells.